

Food and Drug Administration, HHS

§ 340.50

(1) “Do not give to children under 12 years of age.”

(2) “If sleeplessness persists continuously for more than 2 weeks, consult your doctor. Insomnia may be a symptom of serious underlying medical illness.”

(3) “Do not take this product, unless directed by a doctor, if you have a breathing problem such as emphysema or chronic bronchitis, or if you have glaucoma or difficulty in urination due to enlargement of the prostate gland.”

(4) “Avoid alcoholic beverages while taking this product. Do not take this product if you are taking sedatives or tranquilizers, without first consulting your doctor.”

(d) *Directions.* The labeling of the product contains the following information under the heading “Directions”:

(1) *For products containing diphenhydramine hydrochloride identified in §338.10(a).* Adults and children 12 years of age and over: Oral dosage is 50 milligrams at bedtime if needed, or as directed by a doctor.

(2) *For products containing diphenhydramine citrate identified in §338.10(b).* Adults and children 12 years of age and over: Oral dosage is 76 milligrams at bedtime if needed, or as directed by a doctor.

(e) The word “physician” may be substituted for the word “doctor” in any of the labeling statements in this section.

[54 FR 6826, Feb. 14, 1989, as amended at 59 FR 16983, Apr. 11, 1994]

EFFECTIVE DATE NOTE: At 67 FR 72559, Dec. 6, 2002, §338.50 was amended by adding paragraph (c)(5), effective Dec. 8, 2003. For the convenience of the user, the added text is set forth as follows:

**§ 338.50 Labeling of nighttime sleep-aid drug products.**

\* \* \* \* \*

(c) \* \* \*

(5) “Do not use [bullet]<sup>1</sup> with any other product containing diphenhydramine, even one used on skin”.

\* \* \* \* \*

<sup>1</sup> See §201.66(b)(4) of this chapter for definition of bullet symbol.

**PART 340—STIMULANT DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE**

**Subpart A—General Provisions**

Sec.

340.1 Scope.

340.3 Definition.

**Subpart B—Active Ingredient**

340.10 Stimulant active ingredient.

**Subpart C—Labeling**

340.50 Labeling of stimulant drug products.

AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.

SOURCE: 53 FR 6105, Feb. 29, 1988, unless otherwise noted.

**Subpart A—General Provisions**

**§ 340.1 Scope.**

(a) An over-the-counter stimulant drug product in a form suitable for oral administration is generally recognized as safe and effective and is not misbranded if it meets each of the conditions in this part and each of the general conditions established in §330.1.

(b) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.

**§ 340.3 Definition.**

As used in this part:

*Stimulant.* A drug which helps restore mental alertness or wakefulness during fatigue or drowsiness.

**Subpart B—Active Ingredient**

**§ 340.10 Stimulant active ingredient.**

The active ingredient of the product consists of caffeine when used within the dosage limits established in §340.50(d).

**Subpart C—Labeling**

**§ 340.50 Labeling of stimulant drug products.**

(a) *Statement of identity.* The labeling of the product contains the established name of the drug, if any, and identifies

the product as an “alertness aid” or a “stimulant.”

(b) *Indications.* The labeling of the product states, under the heading “Indications,” the following: “Helps restore mental alertness or wakefulness when experiencing fatigue or drowsiness.” Other truthful and nonmisleading statements, describing only the indications for use that have been established and listed in this paragraph (b), may also be used, as provided in § 330.1(c)(2), subject to the provisions of section 502 of the Act relating to misbranding and the prohibition in section 301(d) of the Act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the Act.

(c) *Warnings.* The labeling of the product contains the following warnings under the heading “Warnings”:

(1) “The recommended dose of this product contains about as much caffeine as a cup of coffee. Limit the use of caffeine-containing medications, foods, or beverages while taking this product because too much caffeine may cause nervousness, irritability, sleeplessness, and, occasionally, rapid heart beat.”

(2) “For occasional use only. Not intended for use as a substitute for sleep. If fatigue or drowsiness persists or continues to recur, consult a” (select one of the following: “physician” or “doctor”).

(3) “Do not give to children under 12 years of age.”

(d) *Directions.* The labeling of the product contains the following information under the heading “Directions”: Adults and children 12 years of age and over: Oral dosage is 100 to 200 milligrams not more often than every 3 to 4 hours.

## **PART 341—COLD, COUGH, ALLERGY, BRONCHODILATOR, AND ANTI-ASTHMATIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE**

### **Subpart A—General Provisions**

Sec.

341.1 Scope.

341.3 Definitions.

### **Subpart B—Active Ingredients**

- 341.12 Antihistamine active ingredients.
- 341.14 Antitussive active ingredients.
- 341.16 Bronchodilator active ingredients.
- 341.18 Expectorant active ingredient.
- 341.20 Nasal decongestant active ingredients.

### **Subpart C—Labeling**

- 341.40 Permitted combinations of active ingredients.
- 341.70 Labeling of OTC drug products containing ingredients that are used for treating concurrent symptoms (in either a single-ingredient or combination drug product).
- 341.72 Labeling of antihistamine drug products.
- 341.74 Labeling of antitussive drug products.
- 341.76 Labeling of bronchodilator drug products.
- 341.78 Labeling of expectorant drug products.
- 341.80 Labeling of nasal decongestant drug products.
- 341.85 Labeling of permitted combinations of active ingredients.
- 341.90 Professional labeling.

AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.

### **Subpart A—General Provisions**

#### **§ 341.1 Scope.**

(a) An over-the-counter cold, cough, allergy, bronchodilator, or anti-asthmatic drug product in a form suitable for oral, inhalant, or topical administration is generally recognized as safe and effective and is not misbranded if it meets each of the conditions in this part and each of the general conditions established in § 330.1.

(b) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.

[51 FR 35339, Oct. 2, 1986]

#### **§ 341.3 Definitions.**

As used in this part:

(a) *Bronchodilator drug.* A drug used to overcome spasms that cause narrowing of the bronchial air tubes, such as in the symptomatic treatment of the wheezing and shortness of breath of asthma.